Development of 11β-HSD1 inhibitors for the treatment of type 2 diabetes

被引：31
作者：
Hale, Clarence [1 ]
Wang, Minghan [1 ]
机构：
[1] Amgen Inc, Dept Metab Disorders, Thousand Oaks, CA 91320 USA
来源：
MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2008年 / 8卷 / 07期
关键词：
11 beta-hydroxysteroid dehydrogenase; glucocorticoid receptor; cortisol; ex vivo activity; insulin resistance; Cushing's syndrome;
D O I：
10.2174/138955708784567421
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Glucocorticoid action is linked to the development of obesity and insulin resistance. Inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) has been proposed as a strategy to suppress glucocorticoid action in a tissue-specific manner. A large variety of 11 beta-HSD1 inhibitor classes are under investigation by the pharmaceutical industry to treat type 2 diabetes and obesity.
引用
收藏
页码：702 / 710
页数：9
相关论文
共 50 条
  • [21] Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11β-HSD1:: Novel therapeutic agents for the treatment of metabolic syndrome
    Gu, X
    Dragovic, J
    Koo, GC
    Koprak, SL
    LeGrand, C
    Mundt, SS
    Shah, K
    Springer, MS
    Tan, EY
    Thieringer, R
    Hermanowski-Vosatka, A
    Zokian, HJ
    Balkovec, JM
    Waddell, ST
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (23) : 5266 - 5269
  • [22] Increased Skeletal Muscle 11βHSD1 mRNA Is Associated with Lower Muscle Strength in Ageing
    Kilgour, Alixe H. M.
    Gallagher, Iain J.
    MacLullich, Alasdair M. J.
    Andrew, Ruth
    Gray, Calum D.
    Hyde, Philippa
    Wackerhage, Henning
    Husi, Holger
    Ross, James A.
    Starr, John M.
    Chapman, Karen E.
    Fearon, Kenneth C. H.
    Walker, Brian R.
    Greig, Carolyn A.
    PLOS ONE, 2013, 8 (12):
  • [23] 11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess
    Morgan, Stuart A.
    McCabe, Emma L.
    Gathercole, Laura L.
    Hassan-Smith, Zaki K.
    Larner, Dean P.
    Bujalska, Iwona J.
    Stewart, Paul M.
    Tomlinson, Jeremy W.
    Lavery, Gareth G.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (24) : E2482 - E2491
  • [24] Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome
    Wang, MH
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2006, 7 (04) : 319 - 323
  • [25] Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks
    Freude, S.
    Heise, T.
    Woerle, H. -J.
    Jungnik, A.
    Rauch, T.
    Hamilton, B.
    Schoelch, C.
    Huang, F.
    Graefe-Mody, U.
    DIABETES OBESITY & METABOLISM, 2016, 18 (05) : 483 - 490
  • [26] Assay optimization and kinetic profile of the human and the rabbit isoforms of 11β-HSD1
    Castro, Arturo
    Zhu, Jeff X.
    Alton, Gordon R.
    Rejto, Paul
    Ermolieff, Jacques
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 357 (02) : 561 - 566
  • [27] Recent advances in the study of 11β-Hydroxysteroid dehydrogenase type 2 (11β-HSD2)Inhibitors
    Zhou, Chunchun
    Ye, Fan
    Wu, He
    Ye, Hui
    Chen, Quanxu
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2017, 52 : 47 - 53
  • [28] 11β-HSD1 Inhibition Rescues SAMP8 Cognitive Impairment Induced by Metabolic Stress
    Puigoriol-Illamola, Dolors
    Leiva, Rosana
    Vazquez-Carrera, Manel
    Vazquez, Santiago
    Grinan-Ferre, Christian
    Pallas, Merce
    MOLECULAR NEUROBIOLOGY, 2020, 57 (01) : 551 - 565
  • [29] 11β-HSD1 reduces metabolic efficacy and adiponectin synthesis in hypertrophic adipocytes
    Koh, Eun Hee
    Kim, Ah-Ram
    Kim, Hyunshik
    Kim, Jin Hee
    Park, Hye-Sun
    Ko, Myoung Seok
    Kim, Mi-Ok
    Kim, Hyuk-Joong
    Kim, Bum Joong
    Yoo, Hyun Ju
    Kim, Su Jung
    Oh, Jin Sun
    Woo, Chang-Yun
    Jang, Jung Eun
    Leem, Jaechan
    Cho, Myung Hwan
    Lee, Ki-Up
    JOURNAL OF ENDOCRINOLOGY, 2015, 225 (03) : 147 - 158
  • [30] Why is 11β-hydroxy steroid dehydrogenase type 1 facing the endoplasmic reticulum lumen?: Physiological relevance of the membrane topology of 11β-HSD1
    Odermatt, A
    Atanasov, AG
    Balazs, Z
    Schweizer, RAS
    Nashev, LG
    Schuster, D
    Langer, T
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2006, 248 (1-2) : 15 - 23
12345